GABA: body fat inhibitor and insulin booster
In almost every supplement store you can buy capsules with gamma-aminobutyric acid [GABA]. GABA is a sleep promoter and a growth hormone enhancer , but supplementation with GABA can also help fat people stay healthy. According to researchers at the University of California Los Angeles, GABA inhibits the increase in fat mass if you eat more calories than you burn. That's because GABA makes your cells more sensitive to insulin.

GABA

The more body fat you have, the more immune your cells become to insulin. This is mainly because large fat reserves start to ignite, and they release substances that sabotage the action of insulin.
The researchers already published animal studies in 2004 in which GABA [structural formula above] slows down that process. [J Immunol. 2004 Oct 15; 173 (8): 5298-304.]


Study
In another animal study, which appeared in PLoS One in 2011, the researchers fattened mice for 20 weeks of fat with a high fat diet [HFD]. Half of the animals received GABA via the drinking water.

The human equivalent of the dose used was 800-1200 mg of GABA per day.
Results
Supplementation with GABA did not inhibit food intake, but did increase weight gain. GABA supplementation inhibited the growth of fat mass.




When the researchers administered both glucose and insulin to their test animals, the glucose disappeared more quickly from the blood of the mice receiving GABA. This implies that GABA increased insulin sensitivity.



There were fewer immune cells in the fat tissues of the GABA mice than in the other group. This means that the inflammation in the fatty tissue was less strong. GABA probably works through the immune system.
When the 20 weeks were over, the researchers gave their mice standard food again, but they continued with the supplementation. Body weight and glucose levels stabilized in the GABA group, but deteriorated in the other group.


Conclusion
" Given that GABA mainly acts on the peripheral GABA receptors and is safefor human consumption, GABA and other GABAA-R agonists may be valuable for the prevention and treatment of obesity and type-2 diabetes mellitus in the clinic, " conclude the researchers.

Jide Tian, ​​the lead author of the study, and research leader Daniel Kaufman are sure of their case. So sure that they patented the method they discovered. [EP 2621282 A2.]
Source:
PLoS One. 2011; 6 (9): e25338.